Forwarded from Advanced Lectures in Clinical Immunology & Cellular Therapeutics (Pooya Farhangnia)
🔴داروهاى تارگت كننده ايميون چك پوينت هاى مهارى در درمان سرطان مثانه
🔵Atezolizumab (Tecentriq®): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer and as a first-line treatment for patients who are ineligible for cisplatin chemotherapy
🔵Avelumab (Bavencio®): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer
🔵Durvalumab (Imfinzi™): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer
🔵Nivolumab (Opdivo®): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer
🔵Pembrolizumab (Keytruda®): targets the PD-1/PD-L1 pathway; approved for advance
https://www.cancerresearch.org/immunotherapy/cancer-types/bladder-cancer
@Immunology_Board
@Medical_eImmunology
@USERN_net
@Lab_Science
#iTACT #ImmunoTACT #Immunotherapy #Cancer
🔵Atezolizumab (Tecentriq®): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer and as a first-line treatment for patients who are ineligible for cisplatin chemotherapy
🔵Avelumab (Bavencio®): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer
🔵Durvalumab (Imfinzi™): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer
🔵Nivolumab (Opdivo®): targets the PD-1/PD-L1 pathway; approved for advanced bladder cancer
🔵Pembrolizumab (Keytruda®): targets the PD-1/PD-L1 pathway; approved for advance
https://www.cancerresearch.org/immunotherapy/cancer-types/bladder-cancer
@Immunology_Board
@Medical_eImmunology
@USERN_net
@Lab_Science
#iTACT #ImmunoTACT #Immunotherapy #Cancer
Cancer Research Institute
Immunotherapy for Bladder Cancer
The first FDA-approved immunotherapy treatment—Bacillus Calmette-Guérin cancer vaccine—was for bladder cancer in 1990.